This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on X or LinkedIn  

Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

03 Apr 2023

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round. Plutus Investment Group LLP led the round, with participation from new and existing investors including UK-based VC funds Esperante Ventures, Longwall Ventures and Panacea Innovation, alongside entrepreneur and professional investor, Mr BK Lee. Funds will be used to... Read more

NIHR, Oxford Nanopore announce new health study

NIHR, Oxford Nanopore announce new health study

31 Mar 2023

31 March 2023 Oxford Nanopore Technologies plc announces new human health and disease study led by the UK National Institute for Health and Care Research (NIHR) BioResource Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of Nanopore-based molecular sensing technology, today announces its participation in a cohort study led by the UK National Institute for Health and Care Research... Read more

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

29 Mar 2023

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Oxford... Read more

Physiomics & Beyond Blood announce collaboration

Physiomics & Beyond Blood announce collaboration

28 Mar 2023

  Physiomics & Beyond Blood announce collaboration Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has signed an agreement with Beyond Blood Diagnostics Ltd (“Beyond Blood”) (https://beyondblood.co) to analyse data generated during testing of its diagnostic platform using Physiomics’... Read more

Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

03 Mar 2023

OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI award from the NHS AI Lab (joint unit of teams from the Department of Health and Social Care and NHS England and NHS Improvement). Fundings will be deployed to support a large UK clinical trial aimed at evaluating the clinical utility of the company’s OncoProg® test, a digital pathology solution that uses a sophisticated image... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More